RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More!
European Union
advanced therapies
advanced therapy medicinal products (ATMPs)
healthcare
public perception
survey in Europe
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
07
2021
accepted:
23
09
2021
entrez:
12
11
2021
pubmed:
13
11
2021
medline:
13
11
2021
Statut:
epublish
Résumé
Advanced therapy medicinal products (ATMPs) are potential game changers in modern medical care with an anticipated major impact for patients and society. They are a new drug class often referred to as "living drugs," and are based on complex components such as vectors, cells and even tissues. The production of such ATMPs involves innovative biotechnological methods. In this survey, we have assessed the perception of European citizens regarding ATMPs and health care in Europe, in relation to other important topics, such as safety and security, data protection, climate friendly energy supply, migration, and others. A crucial question was to determine to what extent European citizens wish to support public funding of innovations in healthcare and reimbursement strategies for ATMPs. To answer this, we conducted an online survey in 13 European countries (representative of 85.3% of the entire EU population including the UK in 2020), surveying a total of 7,062 European citizens. The survey was representative with respect to adult age groups and gender in each country. Healthcare had the highest ranking among important societal topics. We found that 83% of the surveyed EU citizens were in support of more public funding of technologies in the field of ATMPs. Interestingly, 74% of respondents are in support of cross-border healthcare for patients with rare diseases to receive ATMP treatments and 61% support the reimbursement of very expensive ATMPs within the European health care system despite the current lack of long-term efficacy data. In conclusion, healthcare is a top ranking issue for European Citizens, who additionally support funding of new technologies to enable the wider application of ATMPs in Europe.
Identifiants
pubmed: 34765617
doi: 10.3389/fmed.2021.739987
pmc: PMC8576137
doi:
Types de publication
Journal Article
Langues
eng
Pagination
739987Informations de copyright
Copyright © 2021 Goldsobel, von Herrath, Schlickeiser, Brindle, Stähler, Reinke, Aberman, Ofir, Dessole, Benvenuti, Neves, Reis, Moll and Volk.
Déclaration de conflit d'intérêts
ZA and RO are employed by Pluristem Therapeutics Inc. Haifa, Israel. GD is employed by Innovation Acta S.r.l., Italy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Trends Mol Med. 2019 Feb;25(2):149-163
pubmed: 30711482
Hum Gene Ther. 1995 Jun;6(6):791-803
pubmed: 7548279
Clin Pharmacol Ther. 2017 Jan;101(1):35-38
pubmed: 27709611
Cytotherapy. 2017 Feb;19(2):293-298
pubmed: 27956199
Hum Gene Ther. 2017 Nov;28(11):972-981
pubmed: 28847159
Cell Stem Cell. 2016 Aug 4;19(2):154-157
pubmed: 27374789
Mol Ther. 2018 May 2;26(5):1172-1176
pubmed: 29685384
Nat Biotechnol. 2005 Oct;23(10):1237-9
pubmed: 16211065
Front Immunol. 2020 Feb 18;11:243
pubmed: 32133010
Nat Commun. 2020 Dec 8;11(1):6265
pubmed: 33293538
Cell Stem Cell. 2020 Jun 4;26(6):806-810
pubmed: 32464095
Nature. 2001 May 24;411(6836):410-2
pubmed: 11373641
Hum Gene Ther. 2020 Jan;31(1-2):20-46
pubmed: 31802714
Gene Ther. 2002 Jun;9(11):667-9
pubmed: 12032683
Science. 2000 Jun 9;288(5472):1751
pubmed: 10877693
Stem Cells Transl Med. 2015 Dec;4(12):1373-9
pubmed: 26537392
Tissue Eng Part A. 2019 Jan;25(1-2):1-8
pubmed: 30027831
Nat Genet. 1992 Oct;2(2):93-8
pubmed: 1303270
Trends Biotechnol. 2017 Feb;35(2):100-108
pubmed: 27499276
Expert Opin Biol Ther. 2015 Mar;15(3):315-8
pubmed: 25556839
BMJ. 2020 Oct 21;371:m3734
pubmed: 33087345
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Trends Biotechnol. 2020 Oct;38(10):1099-1112
pubmed: 31982150
EClinicalMedicine. 2019 Feb 02;7:13-14
pubmed: 31193634
Trends Biotechnol. 2019 Feb;37(2):120-123
pubmed: 30017092
Tissue Eng Part B Rev. 2012 Jun;18(3):155-66
pubmed: 22220809
Front Immunol. 2020 May 19;11:1091
pubmed: 32574263
Trends Mol Med. 2019 Jan;25(1):8-19
pubmed: 30497944
Hum Gene Ther. 1992 Oct;3(5):511-8
pubmed: 1420449
Gene. 2013 Aug 10;525(2):162-9
pubmed: 23618815
Lancet Oncol. 2020 Feb;21(2):e104-e116
pubmed: 32007196
Cell Stem Cell. 2016 Sep 1;19(3):293-7
pubmed: 27588746
Mol Ther Methods Clin Dev. 2017 Sep 22;7:15-19
pubmed: 28971109